

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vincent Medical Holdings Limited

永勝醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1612)

VOLUNTARY ANNOUNCEMENT
FDA EMERGENCY USE AUTHORIZATION FOR
INSPIRED™ O2FLO HIGH FLOW RESPIRATORY HUMIDIFIER
AND ACCESSORIES AND
HYPNUS™ ST730 NON-INVASIVE VENTILATOR

This announcement is made by Vincent Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis with the purpose of allowing the investing public to understand the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Group had recently received Emergency Use Authorization (“**EUA**”) from the Food and Drug Administration of the United States (“**FDA**”) for the Inspired™ O2FLO high flow respiratory humidifier (“**O2FLO**”) and accessories and Hypnus™ ST730 non-invasive ventilator (“**ST730**”).

O2FLO is a non-invasive high flow oxygen therapy device intended to deliver warmed and humidified respiratory gases to spontaneously breathing patients. High flow oxygen therapy has been used in the treatment of patients with chronic or acute respiratory distress such as pneumonia, viral pneumonia (e.g. the novel coronavirus disease (“**COVID-19**”)), chronic obstructive pulmonary disease and asthma. High flow oxygen therapy is an emerging therapy developed for respiratory support, it is clinically proven that the utilization of high flow oxygen therapy in appropriate patients can improve oxygenation, reduce patient breathing effort and serve as a safer and more economical alternative to invasive mechanical ventilation. High flow oxygen therapy has been utilized in the treatment of a broad range of patient populations across critical care units, emergency departments and home use.

O2FLO was approved by the Japan’s Ministry of Health, Labour and Welfare in August 2018, the Conformité Européenne (CE) Mark in November 2019 and the National Medical Products Administration (the “NMPA”) of the People’s Republic of China (the “PRC”) in February 2020, respectively. Since the beginning of the COVID-19 pandemic, the Group has shipped over 1,700 units of O2FLO, together with its dedicated accessories (humidification chamber, heated breathing circuits, nasal cannula, etc.), to countries including the PRC, the United Kingdom, Spain, Denmark, Norway, Turkey, Vietnam and South Africa. The Group is working diligently to fulfill its sales order on hand of over 2,000 units for different countries and is currently in distributorship negotiation in the United States.

ST730 was approved by the NMPA in May 2018 and received its CE Mark in November 2018. ST730 is indicated to provide non-invasive positive airway pressure to spontaneously breathing patients weighing over 30 kg with Obstructive Sleep Apnea (OSA) or respiratory insufficiency. It is intended for hospital and home use and is not intended for patients dependent on mechanical ventilation. ST730 has been used in treating the respiratory distress experienced by COVID-19 patients in the PRC since January 2020.

During public health emergencies, FDA can use emergency authorities, including EUA, to make medical products available as quickly as possible by allowing unapproved medical products to reach patients in need when there are no adequate, FDA-approved and available alternatives. These products may include tests to help diagnose diseases, critical medical devices needed by patients or healthcare personnel in the context of a public health crisis, and drugs to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Vincent Medical Holdings Limited
Choi Man Shing
Chairman and Executive Director

Hong Kong, 21 May 2020

As at the date of this announcement, the Board comprises Mr. Choi Man Shing, Mr. To Ki Cheung, Mr. Koh Ming Fai and Mr. Fu Kwok Fu as executive Directors, Mr. Guo Pengcheng as a non-executive Director, and Mr. Mok Kwok Cheung Rupert, Mr. Au Yu Chiu Steven and Prof. Yung Kai Leung as independent non-executive Directors.